Invivyd’s Covid-directed mAb hits Phase III safety goals

Phase 3positivePositive

AI Analysis

Summary

Invivyd's COVID-directed monoclonal antibody has met Phase III safety goals, with the company's CEO expressing intent to expedite US regulatory pathway for a new COVID protection option.

Clinical Trial Data

Phase

Phase III

Outcome Details

Phase III safety goals met

Importance:6/10

Sentiment:

0.70

monoclonal antibodyCOVID-19Phase IIIsafetyclinical development

Related Companies

$OPTN $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 30, 2026 3:19 PM

Read Original